AU2790502A - Pyrimidine derivatives and their use as neuropeptide y receptor ligands - Google Patents

Pyrimidine derivatives and their use as neuropeptide y receptor ligands

Info

Publication number
AU2790502A
AU2790502A AU2790502A AU2790502A AU2790502A AU 2790502 A AU2790502 A AU 2790502A AU 2790502 A AU2790502 A AU 2790502A AU 2790502 A AU2790502 A AU 2790502A AU 2790502 A AU2790502 A AU 2790502A
Authority
AU
Australia
Prior art keywords
neuropeptide
receptor ligands
pyrimidine derivatives
pyrimidine
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2790502A
Other languages
English (en)
Inventor
Volker Breu
Frank Dautzenberg
Patrizio Mattei
Werner Neidhart
Philippe Pflieger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of AU2790502A publication Critical patent/AU2790502A/xx
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2790502A 2000-11-10 2001-11-06 Pyrimidine derivatives and their use as neuropeptide y receptor ligands Pending AU2790502A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00124610 2000-11-10
PCT/EP2001/012818 WO2002038551A1 (en) 2000-11-10 2001-11-06 Pyrimidine derivatives and their use as neuropeptide y receptor ligands

Publications (1)

Publication Number Publication Date
AU2790502A true AU2790502A (en) 2002-05-21

Family

ID=8170342

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2790502A Pending AU2790502A (en) 2000-11-10 2001-11-06 Pyrimidine derivatives and their use as neuropeptide y receptor ligands
AU2002227905A Ceased AU2002227905B2 (en) 2000-11-10 2001-11-06 Pyrimidine derivatives and their use as neuropeptide Y receptor ligands

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2002227905A Ceased AU2002227905B2 (en) 2000-11-10 2001-11-06 Pyrimidine derivatives and their use as neuropeptide Y receptor ligands

Country Status (20)

Country Link
US (1) US6657060B2 (enExample)
EP (1) EP1335906B1 (enExample)
JP (1) JP2004524279A (enExample)
KR (1) KR100611853B1 (enExample)
CN (1) CN1473156A (enExample)
AR (1) AR034700A1 (enExample)
AT (1) ATE340784T1 (enExample)
AU (2) AU2790502A (enExample)
BR (1) BR0115045A (enExample)
CA (1) CA2427350A1 (enExample)
DE (1) DE60123458T2 (enExample)
DK (1) DK1335906T3 (enExample)
ES (1) ES2271100T3 (enExample)
MX (1) MXPA03004136A (enExample)
PA (1) PA8531701A1 (enExample)
PE (1) PE20020603A1 (enExample)
PT (1) PT1335906E (enExample)
UY (1) UY27018A1 (enExample)
WO (1) WO2002038551A1 (enExample)
ZA (1) ZA200302970B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE486842T1 (de) 2002-03-12 2010-11-15 Merck Sharp & Dohme Substituierte amide
AU2003214110A1 (en) * 2002-03-15 2003-09-29 Ciba Specialty Chemicals Holding Inc. 4-aminopyrimidines and their use for the antimicrobial treatment of surfaces
GB0428328D0 (en) * 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process
US7768604B2 (en) * 2005-09-20 2010-08-03 Au Optronics Corporation Transflective liquid crystal display with partially shifted reflectivity curve
KR20080083188A (ko) * 2006-01-11 2008-09-16 아스트라제네카 아베 모르폴리노 피리미딘 유도체 및 요법에서의 그 유도체의용도
GB0616747D0 (en) * 2006-08-24 2006-10-04 Astrazeneca Ab Novel compounds
WO2008023159A1 (en) 2006-08-24 2008-02-28 Astrazeneca Ab Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
US20090325957A1 (en) * 2006-08-24 2009-12-31 Astrazeneca Ab Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
JP2010533161A (ja) * 2007-07-09 2010-10-21 アストラゼネカ アクチボラグ 化合物−９４６
WO2009007750A1 (en) 2007-07-09 2009-01-15 Astrazeneca Ab Morpholino pyrimidine derivatives used in diseases linked to mtor kinase and/or pi3k
JP2010533158A (ja) * 2007-07-09 2010-10-21 アストラゼネカ アクチボラグ 化合物類−９４５
JP2010533159A (ja) * 2007-07-09 2010-10-21 アストラゼネカ アクチボラグ 化合物９４７
WO2010030027A1 (en) 2008-09-10 2010-03-18 Mitsubishi Tanabe Pharma Corporation Aromatic nitrogen-containing 6-membered ring compounds and their use
TW201028410A (en) * 2008-12-22 2010-08-01 Astrazeneca Ab Chemical compounds 610
JP2011201873A (ja) * 2010-03-03 2011-10-13 Mitsubishi Tanabe Pharma Corp 三置換ピリミジン化合物及びそのｐｄｅ１０阻害薬としての使用
US20130237550A1 (en) * 2010-03-11 2013-09-12 Targacept, Inc. Arylvinylazacycloalkane compounds for constipation
SA111320519B1 (ar) 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
WO2015039292A1 (zh) * 2013-09-18 2015-03-26 华安医学股份有限公司 一种活化ampk的化合物及其用途
CN112375042A (zh) * 2020-10-27 2021-02-19 安徽医科大学 三甲氧基苯乙烯基六元环类和吡唑并嘧啶类化合物、制剂及其制备与应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0720467B2 (ja) * 1988-06-15 1995-03-08 松下電器産業株式会社 超音波診断装置
JPH024345A (ja) * 1988-06-15 1990-01-09 Matsushita Electric Ind Co Ltd 超音波変換装置
WO1994007867A1 (en) 1992-09-28 1994-04-14 Pfizer Inc. Substituted pyrimidines for control of diabetic complications
DE69724941T2 (de) 1996-03-21 2004-07-15 Banyu Pharmaceutical Co., Ltd. Aminopyridin-derivate
AU6309698A (en) * 1997-03-12 1998-09-29 Banyu Pharmaceutical Co., Ltd. Drugs containing aminopyridine derivatives as the active ingredient

Also Published As

Publication number Publication date
US6657060B2 (en) 2003-12-02
KR20040004432A (ko) 2004-01-13
KR100611853B1 (ko) 2006-08-11
UY27018A1 (es) 2002-06-20
DK1335906T3 (da) 2007-02-05
CN1473156A (zh) 2004-02-04
ES2271100T3 (es) 2007-04-16
PT1335906E (pt) 2007-01-31
ZA200302970B (en) 2004-07-15
WO2002038551A1 (en) 2002-05-16
PA8531701A1 (es) 2003-06-30
BR0115045A (pt) 2004-02-03
DE60123458D1 (de) 2006-11-09
EP1335906B1 (en) 2006-09-27
DE60123458T2 (de) 2007-08-02
JP2004524279A (ja) 2004-08-12
US20020086858A1 (en) 2002-07-04
PE20020603A1 (es) 2002-07-20
AU2002227905B2 (en) 2006-10-05
ATE340784T1 (de) 2006-10-15
CA2427350A1 (en) 2002-05-16
MXPA03004136A (es) 2003-08-19
EP1335906A1 (en) 2003-08-20
AR034700A1 (es) 2004-03-17

Similar Documents

Publication Publication Date Title
IL156487A0 (en) Carbazole derivatives and their use as neuropeptide y5 receptor ligands
IL141034A0 (en) Uracil compounds and use thereof
AU6931701A (en) Pyrimidine derivatives
IL185461A0 (en) Pyrimidine compounds and their use
AU7860901A (en) Quinazoline derivatives
AU1041802A (en) Tetrahydro-heterocycloazepinyl pyrimidine derivatives
IL155712A0 (en) Aminothiazoles and their use as adenosine receptor antagonists
IL153246A0 (en) Substituted quinazoline derivatives and their use as inhibitors
PL366038A1 (en) Nucleoside compounds and uses thereof
PT1676845E (pt) Novos derivados de quinazolina
SI1170288T1 (en) Diphenylureum derivatives and their use as alpha2/5-HT2c antagonists
IL150934A0 (en) Pyrimidine compounds
MXPA03004136A (es) Derivados de pirimidina y su uso como ligandos del receptor de neuropeptido y (npy).
IL152700A0 (en) Substituted 1-aminoalkyl-lactams and their use as muscarinc receptor antagonists
HUP0401684A3 (en) Nicotinic acid-heterocyclyl-amides and analogous pyrimidine derivatives serving as pesticides
AU2002352476A8 (en) Urea derivatives and their use as vanilloid receptor antagonists
IL139899A0 (en) Uracil compounds and use thereof
HRP20030362A2 (en) Pyrimidine derivatives
AUPQ570100A0 (en) Beta-alanine derivatives and their use as receptor antagonists
IL152474A0 (en) Antihypertensive agents and use
SI1303496T1 (sl) Pirimidinski derivati
HK1059263A (en) Carbazole derivatives and their use as neuropeptide y5 receptor ligands
GB0030989D0 (en) Quinazoline derivatives
GB0015376D0 (en) Quinazoline derivatives
AU2001230617A1 (en) Beta-alanine derivatives and their use as receptor antagonists